Protagonist Therapeutics, Inc. (PTGX)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about Protagonist Therapeutics, Inc. (PTGX)
Go deeper and ask any question about PTGX
Company Performance
Current Price
as of Sep 13, 2024$47.02
P/E Ratio
17.90
Market Cap
$2.77B
Description
Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.
Metrics
Overview
- HQNewark, CA
- SectorHealth Technology
- IndustryBiotechnology
- TickerPTGX
- Price$47.02+3.00%
Trading Information
- Market Cap$2.77B
- Float94.47%
- Average Daily Volume (1m)551,467
- Average Daily Volume (3m)954,071
- EPS$2.78
Company
- Revenue$319.12M
- Rev Growth (1yr)N/A
- Net Income-$30.62M
- Gross Margin78.59%
- EBITDA Margin-909.55%
- EBITDA-$37.90M
- EV$1.57B
- EV/Revenue4.92
- P/E17.90
- P/S9.03
Documents
SEC Filings
Factset Street Account